Skye Bioscience, Inc. (SKYE)

The company's stock experienced a substantial decline of 64.62% over the past 12 months. A major event occurred on October 6, 2025, when Skye Bioscience announced the topline results from its Phase 2a clinical trial (CBeyond) for nimacimab, where the monotherapy arm failed to achieve its primary endpoint, leading to a 60% plummet in the company's shares. Following these results, a class-action securities fraud lawsuit was filed against Skye Bioscience, Inc. and certain executives on November 17, 2025.

There is no publicly available information regarding demand seasonality for Skye Bioscience, Inc.'s products and services.

Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for diseases with unmet medical needs, operating within the biotechnology and pharmaceutical sectors. The company specializes in cannabinoid-derived pharmaceuticals and next-generation molecules that modulate G protein-coupled receptors (GPCRs). Its major product candidates include SBI-100 Ophthalmic Emulsion (SBI-100 OE) for glaucoma and other eye diseases, and Nimacimab for the treatment of obesity, overweight, and metabolic diseases.

Skye Bioscience, Inc. is headquartered in San Diego, California, United States. The company intends to establish partnerships with international pharmaceutical companies to commercialize its products worldwide, indicating a strategic intent for global reach.

Skye Bioscience's brand reputation has been significantly impacted, particularly in late 2025, due to the failure of the nimacimab monotherapy arm in its Phase 2a clinical trial and the subsequent 60% drop in stock price. This event led to a federal securities fraud lawsuit filed in November 2025, alleging that company executives misled investors about the drug candidate's efficacy and prospects, casting a negative light on the company's reputation.

Institutional investors collectively hold 40% of the company's shares, while private equity firms hold 38%, and the general public holds a 14% stake. Insiders, including CEO Punit Dhillon, collectively own 0.5% of the shares. Major institutional owners and shareholders include 5AM Venture Management, LLC, Versant Venture Management, LLC, Baker Bros. Advisors Lp, Schonfeld Strategic Advisors LLC, Vanguard Group Inc, Ensign Peak Advisors, Inc, Driehaus Capital Management Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Sphera Funds Management Ltd., and Alyeska Investment Group, L.P.